Pharmacokinetics
Imitrex is quickly absorbed and reaches its peak concentration in about an hour. Sumatriptan administered subcutaneously has a bioavailability of about 12%. After receiving a 100 mg oral dose or a 25 mg subcutaneous dose, the peak plasma concentrations are around 2 ng/mL. Sumatriptan is primarily excreted in the urine as an unchanged drug when it is administered subcutaneously. It has an elimination half-life of two to three hours. Neither cytochrome P450 enzymes nor monoamine oxidase extensively metabolize sumatriptan.
Warnings for imitrex
If you have a sumatriptan allergy, circulation issues, heart disease, angina (chest pain), blood pressure issues, a history of heart attack or stroke, severe liver disease, uncontrolled hypertension (high blood pressure), or a headache that resembles your migraine headaches, you should not take this medication.
When taking Imitrex, avoid taking any other migraine medication, such as almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), or zolmitriptan (Zomig), within 24 hours of taking that medication. Imitrex should not be taken while you are pregnant. The unborn child could suffer harm. While you are taking this medication and for at least two weeks after your last dose, use birth control to avoid getting pregnant. Assumatriptan can enter breast milk, endangering a nursing infant. If you use this medication, you shouldn't breastfeed. Tell your doctor if you have ever experienced any of the following: heart disease, a heart attack, a stroke, blood pressure issues, liver or kidney disease, seizures or epilepsy, depression, anxiety, or other mental health issues; xanthoma (skin yellowing). Without consulting a doctor, never administer this medication to anyone who is younger than 18.